Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical trial...
AstraZeneca’s Truqap Granted NMPA Approval for Breast Cancer Treatment
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s (AZ, NASDAQ: AZN) Truqap (capivasertib) for...
Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone
Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...
Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGNN) announced that the U.S. Food and Drug Administration (FDA) has...
BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with...
Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment
German pharmaceutical giant Bayer AG (ETR: BAYN) has completed a 70,000-square-foot expansion at its Myerstown,...
Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China
The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...
Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102
Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into...
Eli Lilly’s Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes
U.S. pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has announced positive top-line results from...
3SBio’s 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China
China-based 3SBio Inc. (HKG: 1530) has announced the receipt of Breakthrough Therapy Designation (BTD) from...
NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development
NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed...
La Prairie Holistic Health’s Functional Nutrient Product Approved in Hainan Pilot Zone
Switzerland-based Clinique La Prairie Holistic Health SA has received approval for its functional nutrient product...
GSK’s Arexvy RSV Vaccine Receives Favorable ACIP Vote for Adults Aged 50-59
UK-based pharmaceutical major GlaxoSmithKline (GSK, NYSE: GSK) has announced a favorable vote from the US...
Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy
China-based Gene Cradle has received approval from the National Medical Products Administration (NMPA) to proceed...
Medtronic’s Implantable Defibrillator System Gains NMPA Approval in China
China’s National Medical Products Administration (NMPA) has approved Medtronic’s (NYSE: MDT) endovascular implantable defibrillation electrode...
Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the first patient enrollment in a Phase...
Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice
US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to...
Junion Therapeutics Secures RMB 100 Million Series A Financing for Weight Loss Device
China-based Junion Therapeutics (Xiamen) Co., Ltd has reportedly secured RMB 100 million (USD 13.7 million)...
Eli Lilly Collaborates with BigHat Biosciences to Engineer Advanced Therapeutic Antibodies
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has entered into a collaboration with...